Corporate News
Page 5
Feb 16, 2021
Axion BioSystems makes REPROCELL a distributor of its Maestro systems and consumables
Read Axion BioSystems announcement of Bioserve Biotechnologies Pvt Ltd (REPROCELL) as the new distributor of its Maestro systems and consumables in India.
Dec 17, 2020
REPROCELL launches personalized iPSC production service alongside new B2C website for "Personal iPS" customers
Find out more about REPROCELL's announcement that they will launch a new service to generate individual specific induced pluripotent stem cells (iPSC's)
Dec 10, 2020
REPROCELL Becomes VIP Supplier on Scientist.com Biotech Marketplace
Find out about how REPROCELL, an industry leader in the use of human biospecimens for medical research has achieved VIP supplier status on scientist.com
Aug 17, 2020
REPROCELL and VIROCLINICS-DDL Launch New Collaboration in Clinical Research
REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical research projects.
Jul 16, 2020
eTheRNA-led international consortium starts preclinical studies of cross-strain protective COVID-19 mRNA vaccine for high risk populations
Learn more about how eTheRNA's mRNA covid vaccine, developed in partnership with REPROCELL, is designed to be protective against future viral variations.
Jul 15, 2020
REPROCELL announce the launch of StemRNA™ Entero human iPSC-derived intestinal epithelial cells
Find out more about REPROCELL's launch of StemRNA Entero human iPSC-derived intestinal epithelial cells. a more clinically relevant alternative to Caco2 cells.
Jul 15, 2020
REPROCELL’s Personal iPS Service is Launched in Japan
Read more about REPROCELL's exciting new launch of its Personal iPS service, allowing customers to store cells for future regenerative medicine treatment.
Jul 13, 2020
Why eTheRNA's mRNA vaccine may offer a long-term solution to COVID
Find out why eTheRNA's mRNA vaccine may offer a long-term solution to COVID in our interview with REPROCELL's CEO.
Feb 28, 2020
Phase II clinical trial of regenerative medicine product Stemchymal® - Recruitment of first patient
REPROCELL is pleased to announce that the first patient has been registered and been administrated at for the Phase II clinical trial of Stemchyma.
Feb 13, 2020
Prof Stefan Przyborski to give Keynote Address at this year’s SMi 3D Cell Culture Conference
Read the announcement that REPROCELL Europe’s Prof Stefan Przyborski will giving the keynote address on 3D cell culture at the SMi Annual Conference London
Jan 16, 2020
Patients with IBD absorb drugs differently from healthy individuals
Read about how a recent study by researchers from REPROCELL found that IBD patients display different drug absorption profiles to healthy individuals.
Jan 14, 2020
REPROCELL can now predict oral bioavailability in fresh IBD tissue
REPROCELL (Biopta) today announced that they can predict test article permeability using gastrointestinal resections from IBD donors.
Dec 23, 2019
Early understanding of pharmacology and genomics can improve precision medicine strategies
REPROCELL announce the successful publication of a novel study in pharmacology and genomics to improve strategies for precision medicine.
Nov 13, 2019
Lantern Pharma Selects REPROCELL Inc., for Drug Screening and Biomarker Discovery Services
Lantern Pharma, a biotech leveraging A.I. and machine learning, has selected REPROCELL Inc. to provide drug screening and drug sensitivity services.
Nov 04, 2019
Appointment of New Distributor in Thailand
Read about the REPROCELL groups distributorship agreement with A.N.H. Scientific Marketing Co. Ltd. to distribute REPROCELL’s products and services in Thailand
Oct 25, 2019
REPROCELL Receives MSCRF Grant to Accelerate Stem Cell Drug Discovery Capability for Enabling Neuronal Disease Research and Drug Development
REPROCELL will apply the funding towards the development of stem cell banking for iPSCs and NSCs derived from various neurodegenerative disease patients.
Sep 25, 2019
PRESS RELEASE: REPROCELL and NeuCyte enter distribution agreement in North America and Europe
This new distributorship will grant REPROCELL customers access to NeuCyte's pure and ready-to-use iPSC-derived glutamatergic and GABAergic induced neurons.
Aug 28, 2019
PRESS RELEASE: Axion BioSystems make REPROCELL a product distributor
Axion BioSystems has announced REPROCELL as the new distributor of its Maestro products in Japan. Read the official Press Release at reprocell.com
Aug 22, 2019
PRESS RELEASE: ABLE Biott Bioreactors now available in Europe
REPROCELL announce the launch of ABLE Biott Bioreactors in Europe. The lab-scale system will allow researchers to culture stem cells in suspension.
May 13, 2019
REPROCELL Launches cGMP suite in Kawasaki to Accelerate Development of iPSC-derived Glial Progenitors for treatment of CNS disorders
REPROCELL Inc. today announced that it has established the current good manufacturing practice (cGMP) cell processing suite at Life Innovation Center (LIC) in Tonomachi area in Kawasaki City for production of iPS Cell-derived Glial Progenitors (iGRP) for treatment of CNS disorders.